InvestSMART

PYC Therapeutics Limited (ASX: PYC) - Announcements

Current share price for PYC : $1.880 0.055 (2.84%)+

ASX company news and announcements for PYC Therapeutics Limited (PYC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PYC Therapeutics Limited (PYC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PYC Therapeutics Limited (PYC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PYC Therapeutics Limited (PYC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$1,850 FNN interview N Woolf Pfizer Deal, Goals for 2011 17 Feb 2011 10:31AM $0.076 $1.880 risen by 2,373.68%
$1,850 Appendix 4C - quarterly 28 Jan 2011 5:47PM $0.070 $1.880 risen by 2,585.71%
$1,850 Phylogica Accesses Novel Half-Life Extension Technology 13 Jan 2011 1:43PM $0.078 $1.880 risen by 2,310.26%
$1,850 Phylogica Signs Collaboration and Licensing Deal with Pfizer 20 Dec 2010 8:45AM $0.066 $1.880 risen by 2,748.48%
$1,850 Interview Nick Woolf CFO and VP Corp Development 16 Dec 2010 10:06AM $0.057 $1.880 risen by 3,198.25%
$1,850 MedImmune drug discovery activities commence 2 Nov 2010 1:01PM $0.051 $1.880 risen by 3,586.27%
$1,850 Appendix 4C - quarterly 29 Oct 2010 3:24PM $0.070 $1.880 risen by 2,585.71%
$1,850 PHYLOGICA AND ROCHE COMPLETE FIRST STAGE OF PARTNERSHIP 21 Oct 2010 10:51AM $0.048 $1.880 risen by 3,816.67%
$1,850 Preliminary Final Report 31 Aug 2010 5:28PM $0.061 $1.880 risen by 2,981.97%
$1,850 Renounceable Issue Prospectus 30 Aug 2010 6:56PM $0.060 $1.880 risen by 3,033.33%
$1,850 Fully Underwritten Renouncable Rights Issue 26 Aug 2010 9:22AM $0.060 $1.880 risen by 3,033.33%
$1,850 Trading Halt 23 Aug 2010 5:42PM $0.075 $1.880 risen by 2,406.67%
$1,850 Phylogica Signs Agreement with MedImmune / AstraZeneca 18 Aug 2010 9:34AM $0.079 $1.880 risen by 2,279.75%
$1,850 Reinstatement to Official Quotation 18 Aug 2010 9:33AM $0.079 $1.880 risen by 2,279.75%
$1,850 Suspension from Official Quotation 5 Aug 2010 9:17AM $0.084 $1.880 risen by 2,138.10%
$1,850 Trading Halt 3 Aug 2010 3:18PM $0.084 $1.880 risen by 2,138.10%
$1,850 Appendix 4C - quarterly 30 Jul 2010 4:13PM $0.055 $1.880 risen by 3,318.18%
$1,850 Appendix 4C - quarterly 30 Apr 2010 1:59PM $0.080 $1.880 risen by 2,250%
$1,850 New Patent Allowance 2 Mar 2010 1:37PM $0.082 $1.880 risen by 2,192.68%
$1,850 Half Yearly Report and Accounts 24 Feb 2010 6:00PM $0.095 $1.880 risen by 1,878.95%
$1,850 Appendix 4C - quarterly 29 Jan 2010 1:24PM $0.100 $1.880 risen by 1,780%
$1,850 Agreement with Major UK company to Build New Drugs 18 Jan 2010 12:58PM $0.125 $1.880 risen by 1,404%
$1,850 Phylogica Signs Agreement with Roche 18 Dec 2009 5:10PM $0.130 $1.880 risen by 1,346.15%
$1,850 Trading Halt 17 Dec 2009 9:54AM $0.130 $1.880 risen by 1,346.15%
$1,850 Reinstatement to official quotation 8 Dec 2009 4:39PM $0.120 $1.880 risen by 1,466.67%

851 - 875 of 954 results

Page 35 of 39

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.